Clinical trial
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00032110 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00032110 |
|---|---|
| Title | Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer |
| Official title | A Phase II Study of OSI-774 in Metastatic Colorectal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis |
| Enrollment | 30 |
| Start date | Jan 1, 2002 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 15, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: